Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome

自身抗体作为治疗后莱姆病综合征的预测标记

基本信息

  • 批准号:
    10737996
  • 负责人:
  • 金额:
    $ 55.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-05 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT As an organism that persists in its natural hosts for long periods of time, Borrelia burgdorferi, the causative agent of Lyme disease, has adapted many strategies for survival and evasion of host immune responses. It has a very small genome and is unable to produce many essential nutrients for itself and is instead, dependent upon utilizing them from its environment. We have recently shown that B. burgdorferi is able to acquire host phospholipids and deploy them, intact, in its membrane. A cost of utilizing host phospholipids is that it may result in production, or de-repression of autoantibodies to host phospholipid targets. Indeed, in our preliminary studies, we found that mice and humans infected with B. burgdorferi produce antibodies to host phospholipids that the organism itself does not produce. Antibodies to phospholipids arise quicker than other antibodies to B. burgdorferi and also appear to resolve more quickly, as might be expected since autoantibody production is typically tightly regulated. However, in patients with PTLDS as compared with patients who resolve their symptoms after treatment for Lyme, there appears to be increased levels of anti-phospholipid antibodies. It is unknown whether these antibodies may be pathogenic or are just a marker for PTLDS. In this proposal, we will explore the development of anti-lipid/phospholipid antibodies during Lyme disease and their potential role in PTLDS. In Aim 1, we will determine the extent of anti-lipid/phospholipid development at different stages of disease and determine their relationship to disease resolution/persistent symptoms in patients with Lyme disease. In Aim 2, we will examine binding of these antibodies to human cells and tissues and look for the presence of immune complexes which are often deposited in auto-immune diseases. Finally, in Aim 3, we will explore a new animal model for PTLDS. A recent study has shown that injection of antibodies from patients with fibromyalgia, a disease with marked similarities to PTLDS in symptoms, into mice results in hypersensitivity to pain and cold as well as changes in locomotion. Histological studies have shown binding of the human antibodies to neural tissues and macrophages. We will test a similar model using serum from patients with PTLDS, recovered Lyme disease and fibromyalgia. In our preliminary studies, we have found increased binding of antibodies from PTLDS patients to mouse brain tissue compared with binding from healthy control antibodies. The discovery of autoantibodies to lipids/phospholipids opens a new area for discovery in the pathogenesis for Lyme disease and may lead to better diagnostic tests and a new understanding of the pathogenesis of this disease.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Linden T Hu其他文献

Case 24-2015
案例24-2015
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Linden T Hu;Athe M. N. Tsibris;John A. Branda
  • 通讯作者:
    John A. Branda

Linden T Hu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Linden T Hu', 18)}}的其他基金

Laboratory for Combinatorial Drug Regimen Design for Resistant and Emerging Pathogens
耐药和新发病原体组合药物方案设计实验室
  • 批准号:
    10596722
  • 财政年份:
    2022
  • 资助金额:
    $ 55.52万
  • 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
  • 批准号:
    10461854
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
  • 批准号:
    10397615
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
  • 批准号:
    10680556
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
  • 批准号:
    10606624
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
  • 批准号:
    10165497
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
  • 批准号:
    10256713
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
  • 批准号:
    10674121
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
Understanding Human Immunological Responses to Ixodes Tick Bites
了解人类对硬蜱叮咬的免疫反应
  • 批准号:
    9807836
  • 财政年份:
    2019
  • 资助金额:
    $ 55.52万
  • 项目类别:
Coping with Stress: Next Generation Approaches to Borrelia burgdorferi Host Adaptation
应对压力:伯氏疏螺旋体宿主适应的下一代方法
  • 批准号:
    9892949
  • 财政年份:
    2017
  • 资助金额:
    $ 55.52万
  • 项目类别:

相似海外基金

Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
  • 批准号:
    DP240100640
  • 财政年份:
    2024
  • 资助金额:
    $ 55.52万
  • 项目类别:
    Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
  • 批准号:
    23K01889
  • 财政年份:
    2023
  • 资助金额:
    $ 55.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10452217
  • 财政年份:
    2022
  • 资助金额:
    $ 55.52万
  • 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10670838
  • 财政年份:
    2022
  • 资助金额:
    $ 55.52万
  • 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
  • 批准号:
    DP200100492
  • 财政年份:
    2020
  • 资助金额:
    $ 55.52万
  • 项目类别:
    Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
  • 批准号:
    407264
  • 财政年份:
    2019
  • 资助金额:
    $ 55.52万
  • 项目类别:
    Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
  • 批准号:
    18K18240
  • 财政年份:
    2018
  • 资助金额:
    $ 55.52万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
  • 批准号:
    17K12379
  • 财政年份:
    2017
  • 资助金额:
    $ 55.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
  • 批准号:
    17K13937
  • 财政年份:
    2017
  • 资助金额:
    $ 55.52万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
  • 批准号:
    8742767
  • 财政年份:
    2014
  • 资助金额:
    $ 55.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了